Influx Healthtech Limited, headquartered in Mumbai, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO) that caters to various sectors including Nutraceuticals, Cosmetics, Ayurvedic products, Veterinary Foods, and Homecare. Since its incorporation in 2020, the company has demonstrated robust financial performance, carving a niche in India's contract manufacturing landscape.

The company is now hitting the capital markets with an SME IPO on the NSE. The public issue comprises a Book Built Issue aggregating to ₹58.57 crores, including a fresh issue of 50 lakh equity shares worth ₹48.00 crores and an Offer for Sale (OFS) of 11 lakh shares totaling ₹10.57 crores.

Influx Healthtech IPO Dates & Key Details:

• IPO Open Date: June 18, 2025

• IPO Close Date: June 20, 2025

• Allotment Finalization: June 23, 2025

• Tentative Listing Date: June 25, 2025

• IPO Price Band: ₹91 to ₹96 per share

• Lot Size: 1,200 shares

• Minimum Retail Investment: ₹1,15,200

• HNI Minimum Investment: ₹2,30,400 (2 lots)

• Market Capitalization at Upper Band: ₹222.24 crores

The issue is being managed by Rarever Financial Advisors Pvt Ltd and the registrar is Maashitla Securities Pvt Ltd. The market maker for the issue is R.K. Stockholding Pvt Ltd.

Grey Market Premium (GMP) and Subscription Status:

As of June 18, 2025, the GMP for Influx Healthtech stands at ₹11, implying a listing premium of 10.56% over the upper price band of ₹96. While GMP is a useful sentiment indicator, it is not a formal price discovery mechanism and should be interpreted cautiously.

The IPO saw a subscription of 1.23x by 11:30 AM on Day 1, reflecting decent early interest, although the final oversubscription figures will be more indicative of investor confidence.

Anchor Investment Details:

Influx Healthtech has raised ₹16.66 crores from anchor investors, allocating 17,36,400 equity shares at ₹96 per share. These shares are a part of the QIB reservation quota, and their early commitment helps boost confidence in the IPO.

Objectives of the IPO:

The net proceeds from the IPO are planned to be used across various verticals of the company's operations:

1. ₹2,260.11 lakhs for setting up a new manufacturing facility for the Nutraceutical division.

2. ₹1,158.58 lakhs for a Veterinary Food manufacturing unit.

3. ₹275.65 lakhs for purchasing machinery for the Homecare and Cosmetic division.

4. Remaining funds will be allocated for general corporate purposes.

These planned capital expenditures will enable the company to expand its multi-segment CDMO services, thereby improving economies of scale and product diversification.

Company Background and Promoters:

The firm is promoted by:

• Mr. Munir Abdul Ganee Chandniwala, with 22+ years in the Nutraceuticals, Cosmetics, and Ayurvedic industry.

• Mrs. Shirin Munir Ahmed Chandniwala, with 12+ years of experience in trading packaging materials.

• Mr. Abdul Ganee Abdul Rasul Chandniwala, with 21 years in pharmaceuticals.

Their domain expertise, combined with the company’s focus on niche healthcare segments, has led to accelerated growth in operations.

Financial Performance:

Influx Healthtech's financials demonstrate a steady growth trajectory:

The company's Revenue from Operations has grown 38% in 2 years, while PAT has nearly doubled from FY23 to FY25.

Valuation Metrics:

• Pre-Issue EPS (FY24): ₹7.36

• Post-Issue EPS (FY24): ₹5.77

• Pre-Issue P/E: 13.04x

• Post-Issue P/E: 16.63x

• Industry P/E Average: 29x

• ROCE (FY24): 49.17%

• ROE (FY24): 36.98%

• RoNW: 36.98%

These figures suggest that while the IPO is priced slightly on the higher side post-issue, it remains below the industry average, which adds to the relative attractiveness of the offer.

Influx Healthtech IPO Review and Recommendation:

Influx Healthtech brings diversified exposure across high-growth segments in healthcare. The promoters’ experience, combined with strong RoCE and RoE, are standout indicators of operational efficiency. The company is also expanding into veterinary foods and homecare segments, offering upside potential.

However, being a relatively new entrant (est. 2020), the business has limited historical resilience, and investors must factor in the risks associated with the SME segment volatility and sectoral regulations.

Recommendation:
This IPO is best suited for risk-tolerant investors seeking short-term listing gains. The 10.56% GMP suggests modest demand, and while financials are solid, the valuation post-issue stretches close to peer levels. Investors should Apply with caution, preferably for listing gains, and only if they can handle short-term volatility.

Disclaimer:
This article is for educational and informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and consultation with SEBI-registered advisors. Market conditions are volatile and subject to change. Neither the author nor the platform is responsible for losses arising from use of this information.

The Upcoming IPOs in this week and coming weeks are Shri Hare-Krishna Sponge Iron, Icon Facilitators, Ace Alpha Tech, Aakaar Medical Technologies, Safe Enterprises Retail Fixtures, Globe Civil Projects, Sambhav Steel Tubes, Ellenbarrie Indutrial Gases, Kalpataru, HDB Financials, AJC Jewel, Mayasheel Ventures.

The Current active IPO are  ArisInfra Solutions, Influx Healthtech, Eppeltone Engineers, Patil Automation, Samay Projects Services.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.